Assaraf YG - Search Results

1

The multi-factorial nature of clinical multidrug resistance in cancer.

Assaraf YG, Brozovic A, Gonçalves AC, Jurkovicova D, Linē A, Machuqueiro M, Saponara S, Sarmento-Ribeiro AB, Xavier CPR, Vasconcelos MH. Assaraf YG, et al. Drug Resist Updat. 2019 Sep;46:100645. doi: 10.1016/j.drup.2019.100645. Epub 2019 Sep 17. Drug Resist Updat. 2019. PMID: 31585396 Review.

2

Determination of multidrug resistance levels in cultured mammalian cells using ornithine decarboxylase activity.

Assaraf YG, Drori S, Bachrach U, Shaugan-Labay V. Assaraf YG, et al. Anal Biochem. 1994 Jan;216(1):97-109. doi: 10.1006/abio.1994.1013. Anal Biochem. 1994. PMID: 8135371

3

The role of passive transbilayer drug movement in multidrug resistance and its modulation.

Eytan GD, Regev R, Oren G, Assaraf YG. Eytan GD, et al. Among authors: assaraf yg. J Biol Chem. 1996 May 31;271(22):12897-902. doi: 10.1074/jbc.271.22.12897. J Biol Chem. 1996. PMID: 8662680 Free article.

4

Targeting an extracellular epitope of the human multidrug resistance protein 1 (MRP1) in malignant cells with a novel recombinant single chain Fv antibody.

Binyamin L, Assaraf YG, Haus-Cohen M, Stark M, Reiter Y. Binyamin L, et al. Among authors: assaraf yg. Int J Cancer. 2004 Jul 20;110(6):882-90. doi: 10.1002/ijc.20177. Int J Cancer. 2004. PMID: 15170671 Free article.

5

The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis.

Assaraf YG. Assaraf YG. Drug Resist Updat. 2006 Aug-Oct;9(4-5):227-46. doi: 10.1016/j.drup.2006.09.001. Epub 2006 Nov 7. Drug Resist Updat. 2006. PMID: 17092765 Review.

6

Molecular basis of antifolate resistance.

Assaraf YG. Assaraf YG. Cancer Metastasis Rev. 2007 Mar;26(1):153-81. doi: 10.1007/s10555-007-9049-z. Cancer Metastasis Rev. 2007. PMID: 17333344 Review.

7

C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells.

Bram EE, Ifergan I, Grimberg M, Lemke K, Skladanowski A, Assaraf YG. Bram EE, et al. Among authors: assaraf yg. Biochem Pharmacol. 2007 Jun 30;74(1):41-53. doi: 10.1016/j.bcp.2007.03.028. Epub 2007 Apr 1. Biochem Pharmacol. 2007. PMID: 17481587

8

Riboflavin concentration within ABCG2-rich extracellular vesicles is a novel marker for multidrug resistance in malignant cells.

Ifergan I, Goler-Baron V, Assaraf YG. Ifergan I, et al. Among authors: assaraf yg. Biochem Biophys Res Commun. 2009 Feb 27;380(1):5-10. doi: 10.1016/j.bbrc.2008.12.168. Epub 2009 Jan 10. Biochem Biophys Res Commun. 2009. PMID: 19138668

9

Chemotherapeutic drug-induced ABCG2 promoter demethylation as a novel mechanism of acquired multidrug resistance.

Bram EE, Stark M, Raz S, Assaraf YG. Bram EE, et al. Among authors: assaraf yg. Neoplasia. 2009 Dec;11(12):1359-70. doi: 10.1593/neo.91314. Neoplasia. 2009. PMID: 20019844 Free PMC article.

10

Structure and function of ABCG2-rich extracellular vesicles mediating multidrug resistance.

Goler-Baron V, Assaraf YG. Goler-Baron V, et al. Among authors: assaraf yg. PLoS One. 2011 Jan 24;6(1):e16007. doi: 10.1371/journal.pone.0016007. PLoS One. 2011. PMID: 21283667 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

239 results

Search Page